 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LBL-003 / Leads Biolabs
Trial completion, Enrollment change: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (clinicaltrials.gov) - May 21, 2024
P1, N=18, Completed, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Recruiting --> Completed | N=36 --> 18
- | LBL-003 / Leads Biolabs
Trial completion date, Trial primary completion date, Metastases: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 11, 2023
P1, N=36, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Recruiting --> Completed | N=36 --> 18 Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> Mar 2024
- | LBL-003 / Leads Biolabs
Trial primary completion date, Metastases: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 21, 2022
P1, N=36, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> Mar 2024 Trial primary completion date: Oct 2022 --> Oct 2023
- || LBL-003 / Leads Biolabs
Enrollment open, Metastases: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 10, 2021
P1, N=36, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial primary completion date: Oct 2022 --> Oct 2023 Not yet recruiting --> Recruiting
- || LBL-003 / Leads Biolabs
New P1 trial, Metastases: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 12, 2021
P1, N=36, Not yet recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd